Norrlands University Hospital

At Norrlands University Hospital the pediatric oncology team concentrates on neoplasms in children, especially high‑risk neuroblastoma. The trials aim to improve event‑free survival by comparing intensive chemotherapy schedules and refined radiotherapy approaches.

• Intensive high‑dose chemotherapy regimens
• Optimized radiotherapy dosing for residual disease
• Chemoimmunotherapy combinations for poor responders
• Long‑term survival outcomes assessment

The research supports international collaboration and seeks to set new standards for treating children with aggressive neuroblastoma.

The department also runs studies on osteosarcoma, targeting patients from initial diagnosis through relapse. The goal is to evaluate novel therapeutic sequences that could raise cure rates.

• Evolutionary study platform spanning diagnosis to relapse
• Multicenter coordination across Europe
• Integration of emerging agents with standard surgery
• Assessment of disease‑free survival

By linking laboratory insights with clinical practice, the site hopes to deliver more effective options for young patients with bone cancer.

A separate trial examines the use of cabozantinib as a maintenance option after first‑line treatment, comparing it to best supportive care. The study measures whether the targeted drug can extend event‑free survival in children who have achieved remission or have stable residual disease.

• Maintenance after chemotherapy
• Randomized comparison with supportive care
• Evaluation in complete remission and stable disease groups
• Long‑term outcome tracking

This investigation is part of a broader European platform aiming to personalize post‑remission strategies for pediatric cancers.